News
Revenue of $8.55 billion increased 1% sequentially and decreased 6% year on year GAAP EPS of $0.74 increased 28% sequentially ...
Among these, GlaxoSmithKline and Debiopharm/Merck have drug candidates that are in the most advanced phase of development—Phase III clinical trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results